ci 988 has been researched along with Depressive Disorder in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagot, RC; Berton, O; Cahill, ME; Dietz, DM; Fallon, B; Feng, J; Ferguson, D; Harrigan, E; Joshi, T; Ku, SM; Mazei-Robison, M; Nestler, EJ; Robison, AJ; Vialou, V; Winstanley, CA | 1 |
| Adams, JB; Costa, J; Cutler, NR; Greiner, M; Pande, AC; Pierce, MW; Pyke, RE; Schweizer, E; Wilcox, CS; Wisselink, PG | 1 |
1 trial(s) available for ci 988 and Depressive Disorder
| Article | Year |
|---|---|
A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Colonic Diseases, Functional; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Male; Meglumine; Panic Disorder; Personality Inventory; Phobic Disorders; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Somatoform Disorders; Treatment Outcome | 1995 |
1 other study(ies) available for ci 988 and Depressive Disorder
| Article | Year |
|---|---|
Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain Mapping; Cholecystokinin; Chronic Disease; Depressive Disorder; Indoles; Limbic System; Male; Meglumine; Mice; Mice, Inbred C57BL; Neural Pathways; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Receptor, Cholecystokinin B; Social Dominance; Stress, Psychological | 2014 |